Latest Leadership News

Delta Lithium reports robust December quarter results with significant gold drilling successes at Mt Ida and progress on lithium development at Yinnetharra, alongside strategic leadership changes and asset sales.

Mad Paws Holdings Limited reported a milestone positive cash EBITDA of $0.3 million in Q2 FY25, driven by strong marketplace growth and operational efficiencies. The company is amplifying its market presence with a $5.25 million brand campaign in partnership with Seven West Media.

Credit Corp Group reported steady H1 FY25 results with operational improvements and confirmed full-year guidance, driven by growth in US debt buying and stable Australian/New Zealand lending.

Top End Energy has taken a major step by acquiring the Kansas Natural Hydrogen Project and advancing its exploration footprint in Australia's Beetaloo Sub-Basin, positioning itself at the forefront of natural hydrogen and unconventional gas development.

RMA Global Limited has reported its first cash flow positive quarter since listing, alongside a 9% revenue increase driven by strong US and ANZ market performance and the strategic acquisition of Curated Social.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Capricorn Metals delivered a robust December quarter with rising gold production, record cash flow, and strategic expansions, positioning itself strongly for FY25 targets.

Articore Group reveals a strategic restructure delivering significant cost savings and improved margins, even as marketplace revenue continues to decline. The launch of a new product, Dashery, aims to diversify revenue streams.

Doctor Care Anywhere delivered positive cash flow and revenue growth at the top of guidance in Q4 2024, while navigating a strategic shift with new leadership appointments and the closure of secondary care pathways.

NGX Limited reports significant progress in its uranium exploration in Namibia and graphite development in Malawi, alongside strategic leadership changes and a strong financial position.

Island Pharmaceuticals reports promising safety and anti-dengue activity in its Phase 2a trial of ISLA-101 and has commenced the Phase 2b therapeutic arm, backed by a fresh A$3.5 million capital raise.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.